No Data
Procept Biorobotics Earnings Call Highlights Growth and Challenges
PROCEPT BioRobotics | 10-K: FY2024 Annual Report
Wells Fargo Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Cuts Target Price to $105
A Quick Look at Today's Ratings for PROCEPT BioRobotics(PRCT.US), With a Forecast Between $77 to $105
Goldman Sachs' research throws cold water on the situation: the turning point for humanoid robot technology remains unclear, and meaningful applications will take at least another five years!
Goldman Sachs believes that the humanoid robot H1 has only 19 degrees of freedom, making it still unable to handle complex and detailed tasks. At least in the next 2-3 years, it will be difficult for humanoid robots to achieve the same work efficiency as human workers. Meaningful applications are not expected for another 5-10 years.
PROCEPT BioRobotics Full Year 2024 Earnings: EPS Misses Expectations
Tesla 1st : Agreed